<!DOCTYPE html>
<html lang="en">

    <head>
        <meta charset="UTF-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <title>Casebook</title>
        <link rel="stylesheet" href="assets/css/bootstrap.min.css">
        <link rel="stylesheet" href="assets/css/style.css">
        
        <meta name="robots" content="noindex,nofollow">

    </head>

    <body class="hide">


        <div class="modal" tabindex="-1" role="dialog">
            <div class="modal-dialog modal-dialog-centered" id="PasswordModal" role="document">
                <div class="modal-content">
                    <div class="modal-body text-white">
                        <div class="landing-modal">
                            <p class="text-center">
                                This learning program is intended for <br> healthcare professionals only. 
                            </p>
                            <form action="#" class="d-flex flex-column mt-3 pt-1">
                                <label class="mb-1" for="password">Password</label>
                                <input id="password" type="password" value="1234">
                                <label class="mb-1 d-none" id="bad-password">Bad password!</label>
                                <input type="submit" value="Submit">
                            </form>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <header class="bg-white">
            <div class="container d-flex justify-content-between align-items-center">

                <a href="index.html" class="logo">
                    <img src="assets/images/logo.svg" alt="">
                </a>
                <p class="text-center text-pink text-bold d-md-block d-none">
                    <span class="d-block text-deeppink">
                        casebook on Comorbidities in RA:
                    </span>
                    A Patient-focused Multidisciplinary Perspective
                </p>
                <div class="language d-flex align-items-center">
                    <a class="" href="index.html">
                        <img class="me-2 d-none d-md-block" src="assets/images/icons/home.svg" alt="">
                    </a>
                    <a class="language-switcher" href="#">
                    <span class="text-deeppink pt-0 pt-md-1 pt-lg-2">
                        Fr
                    </span>
                </a>
                </div>
            </div>
        </header>
        <section class="wrapper landing-content mb-5 pb-5">
            <div class="container d-flex flex-wrap justify-content-between">
                <div class="left-sidebar text-center">
                    <ul>
                        <li>
                            <a class="pink-button" href="case-studies.html">
                                Case studies
                            </a>
                        </li>
                        <li>
                            <a class="pink-button" href="knowledge-test.html">
                                Knowledge tests
                            </a>
                        </li>
                        <li>
                            <a class="pink-button reference-button" href="references.html">
                                References
                            </a>
                        </li>
                        <li>
                            <a class="pink-button" href="events.html">
                                Events
                            </a>
                        </li>
                        <li>
                            <a class="pink-button" href="associations.html">
                                Associations
                            </a>
                        </li>
                        <li>
                            <a class="pink-button" href="about-section.html">
                                About Section 2/3 credit
                            </a>
                        </li>
                        <li class="d-none d-md-block">
                            <a class="pink-button" target="_blank" href="https://www.surveymonkey.com/r/RAcasebook">
                                Evaluation form
                                <span class="d-block mb-1">
                                    (for self-directed learning participants only)
                                </span>
                            </a>
                        </li>
                    </ul>
                </div>
                <div class="middle-content">
                    <div id="references" class="box-item diff-1 references mt-0 mb-4">
                        <h3 class="common-title text-deeppink mb-3">
                            References (RA and risk factors for MACE):
                        </h3>
                        <p class="mb-2">1. Colaco K, Ocampo V, Ayala AP, <i>et al</i>. Predictive Utility of Cardiovascular
                            Risk
                            Prediction Algorithms in Inflammatory Rheumatic Diseases: A Systematic Review. J Rheumatol 2020;
                            47:928-38.</p>
                        <p class="mb-2">2. Cui K, Movahedi M, Bombardier C, <i>et al</i>. Cardiovascular risk factors are
                            negatively associated with rheumatoid arthritis disease outcomes. Therapeutic Advances in
                            Musculoskeletal Disease 2021; 13:1-10. </p>
                        <p class="mb-2">3. Agca R, Heslinga SC, Rollefstad S, <i>et al</i>. EULAR recommendations for
                            cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of
                            inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1):17-28. </p>
                        <p class="mb-2">4. Provan SA, Semb AG, Hisdal J, <i>et al</i>. Remission is the goal for
                            cardiovascular
                            risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann
                            Rheum Dis 2011; 70(5):812-7.</p>
                        <p class="mb-2">5. Myasoedova E, Chandran A, Ilhan B, <i>et al</i>. The role of rheumatoid arthritis
                            (RA)
                            flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis
                            2016; 75:560-5. </p>
                        <p class="mb-2">6. Stoffer MA, Schoels MM, Smolen JS, <i>et al</i>. Evidence for treating rheumatoid
                            arthritis to target: results of a systematic literature search update. Ann Rheum Dis 2016;
                            75(1):16-22. </p>
                        <p class="mb-2">7. Guin A, Chatterjee Adhikari M, Chakraborty S, <i>et al</i>. Effects of disease
                            modifying
                            anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been
                            detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum 2013;
                            43(1):48-54.</p>
                        <p class="mb-2">8. Tobe SW, Gilbert RE, Jones C, <i>et al</i>. Diabetes Canada 2018 Clinical
                            Practice
                            Guidelines for the Prevention and Management of Diabetes in Canada: Treatment of Hypertension.
                            Can J Diabetes 2018; 42(Suppl 1):S186.</p>
                        <p class="mb-2">9. Leung AA, Daskalopoulou SS, Dasgupta K, <i>et al</i>. Hypertension Canada.
                            Hypertension
                            Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of
                            Hypertension in Adults. Can J Cardiol 2017; 33(5):557-76.</p>
                        <p class="mb-2">10. Mancini GB, Hegele RA, Leiter LA. Diabetes Canada 2018 Clinical Practice
                            Guidelines for the Prevention and Management of Diabetes in Canada: Dyslipedimia. Can J Diabetes
                            2018; 42(Suppl 1):S178-S185.</p>
                        <p class="mb-2">11. Pearson GJ, Thanassoulis G, Anderson TJ, <i>et al</i>. 2021 Canadian
                            Cardiovascular
                            Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular
                            Disease in Adults. Can J Cardiol 2021; 37(8):1129-50. </p>
                        <p class="mb-2">12. Gomides APM, Albuquerque CP, Santos ABV, <i>et al</i>. High Levels of
                            Polypharmacy in
                            Rheumatoid Arthritis-A Challenge Not Covered by Current Management Recommendations: Data From a
                            Large Real-Life Study. J Pharm Pract 2021; 34(3):365-71.</p>
                        <p class="mb-2">13. Elmets CA, Leonardi CL, Davis DMR, <i>et al</i>. Joint AAD-NPF guidelines of
                            care for
                            the management and treatment of psoriasis with awareness and attention to comorbidities. J Am
                            Acad Dermatol 2019; 80(4):1073-113. </p>
                        <p class="mb-2">14. Ridker PM, Buring JE, Rifai N, <i>et al</i>. Development and validation of
                            improved
                            algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.
                            JAMA 2007; 297:611-9. </p>
                        <p class="mb-2">15. Ridker PM, Paynter NP, Rifai N, <i>et al</i>. C-reactive protein and parental
                            history
                            improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation
                            2008; 118:2243-51.</p>
                        <p class="mb-2">16. Yu Z, Yang N, Everett BM, <i>et al</i>. Impact of Changes in Inflammation on
                            Estimated
                            Ten-Year Cardiovascular Risk in Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70(9):1392-8.
                        </p>
                        <p class="mb-2">17. Colaco K, Ocampo V, Ayala AP, <i>et al</i>. Predictive Utility of Cardiovascular
                            Risk
                            Prediction Algorithms in Inflammatory Rheumatic Diseases: A Systematic Review. J Rheumatol 2020;
                            47(6):928-38.</p>
                        <p class="mb-2">
                            18. Evans MR, Escalante A, Battafarano DF, <i>et al</i>. Carotid atherosclerosis predicts incident
                            acute
                            coronary syndromes in rheumatoid arthritis. Arthritis Rheum 2011; 63:1211-20.
                        </p>
                        <p class="mb-2">19. Corrales A, Parra JA, González-Juanatey C, <i>et al</i>. Cardiovascular risk
                            stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery
                            Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis.
                            Ann Rheum Dis 2013; 72(11):1764-70.</p>
                        <p class="mb-2">20. Lobo SA, Fischer S. Cardiac Risk Assessment. StatPearls Publishing, 2022.
                            Available at: https://www.ncbi.nlm.nih.gov/books/NBK537146/. Accessed March 2022. </p>
                        <p class="mb-2">21. Haine A, Kavanagh S, Berger JS, <i>et al</i>. International Steering Committee
                            and
                            Investigators of the EUCLID Trial. Sex-Specific Risks of Major Cardiovascular and Limb Events in
                            Patients With Symptomatic Peripheral Artery Disease. J Am Coll Cardiol 2020; 75(6):608-17. </p>
                        <p class="mb-2">22. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic
                            diseases. Nat Rev Rheumatol 2015; 11(12):693-704.</p>
                        <p class="mb-2">23. Vittecoq O, Richard L, Banse C, <i>et al</i>. The impact of smoking on
                            rheumatoid
                            arthritis outcomes. Joint Bone Spine 2008; 85(2):135-8. </p>
                        <p class="mb-2">24. Ontario Medical Association. Education and Prevention Committee Interpretive
                            Bulletin. Specific Neurocognitive Assessment (K032) and Smoking Cessation services (E079 and
                            K039). Available at: www.oma.org/uploadedfiles/oma/media/public/0802epc_bulletin.pdf. Accessed
                            March 2022. </p>
                        <p class="mb-2">25. The Arthritis Society. Self-Management. Available at:
                            https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/rheumatoid-arthritis. Accessed
                            April 2022. </p>
                        <p class="mb-2">26. Guasch-Ferré M, Hu FB, Martínez-González MA, <i>et al</i>. Olive oil intake and
                            risk of
                            cardiovascular disease and mortality in the PREDIMED Study. BMC Med 2014; 13;12:78. </p>
                        <p class="mb-2">27. Ozen G, Pedro S, Holmqvist ME, <i>et al</i>. Risk of diabetes mellitus
                            associated with
                            disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis 2017;
                            76(5):848-54.</p>
                        <p class="mb-2">28. The Arthritis Society. Online Learning Modules. Available at:
                            https://arthritis.ca/support-education/online-learning/. Accessed April 2022.</p>

                    </div>
                    <div id="references" class="box-item diff-1 references mt-0 mb-4">
                        <h3 class="common-title text-deeppink mb-3">
                            References (RA and metabolic syndrome):
                        </h3>

                        <p class="mb-2">1. Sandrin L, Fourquet B, Hasquenoph JM, <i>et al</i>. Transient elastography: a new
                            noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705-13.
                        </p>
                        <p class="mb-2">2. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.
                            National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Methotrexate. Available
                            at: https://www.ncbi.nlm.nih.gov/books/NBK548219/. Accessed March 2022. </p>
                        <p class="mb-2">3. Wang W, Zhou H, Liu L. Side effects of methotraxate therapy for rheumatoid
                            arthritis: A systematic review. European Journal of Medicinal Chemistry 2018; 158(5):502-16.
                        </p>
                        <p class="mb-2">4. Erdbrügger U, de Groot K. Is methotrexate nephrotoxic? Dose-dependency,
                            comorbidities and comedication. Z Rheumatol 2011; 70(7):549-52.</p>
                        <p class="mb-2">5. Drosos A. Methotrexate intolerance in elderly patients with rheumatoid arthritis:
                            what are the alternatives? Drugs Aging 2003; 20(10):723-36. </p>
                        <p class="mb-2">6. Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on
                            haemodialysis. Rheumatology (Oxford) 2006; 45:357-9.</p>
                        <p class="mb-2">7. U.S. FDA. FDA requires warnings about increased risk of serious heart-related
                            events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic
                            inflammatory conditions. Available at:
                            www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death.
                            Accessed March 2022. </p>
                        <p class="mb-2">8. Health Canada. Health Canada safety review finds link between the use of Xeljanz
                            and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer.
                            Available at:
                            https://recalls-rappels.canada.ca/en/alert-recall/health-canada-safety-review-finds-link-between-use-xeljanz-and-xeljanz-xr-tofacitinib.
                            Accessed March 2022. </p>
                        <p class="mb-2">9. Remicade<sup>®</sup> (infliximab) product monograph. Janssen Inc. Revised October
                            15, 2021.</p>
                        <p class="mb-2">10. Ruxience (rituximab) product monograph. Pfizer Canada ULC. Revised July 8, 2020.
                        </p>
                        <p class="mb-2">11. Actemra<sup>®</sup> (tocilizumab) product monograph. Hoffman-La Roche Ltd.
                            Revised January 4, 2021.</p>
                        <p class="mb-2">12. Orencia<sup>®</sup> (abatacept) product monograph. Bristol-Myers Squibb. Revised
                            September 9, 2019.</p>
                        <p class="mb-2">13. Xeljanz<sup>®</sup> (tofacitinib) product monograph. Pfizer Canada ULC. Revised
                            December 9, 2021.</p>

                    </div>
                    <div id="references" class="box-item diff-1 references mt-0 mb-4">
                        <h3 class="common-title text-deeppink mb-3">
                            References (RA and history of malignancy):
                        </h3>
                        <p class="mb-2">1. De Cock D, Hyrich K. Malignancy and rheumatoid arthritis: Epidemiology, risk
                            factors and management. Best Practice &amp; Research Clinical Rheumatology 2018; 32(6):869-86.
                        </p>
                        <p class="mb-2">2. Montastruc F, Renoux C, Dell’Aniello S, <i>et al</i>. Abatacept initiation in rheumatoid
                            arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology
                            (Oxford) 2019; 58(4):683-91. </p>
                        <p class="mb-2">3. Wadström H, Frisell T, Askling J. Anti-Rheumatic Therapy in Sweden (ARTIS) Study
                            Group. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis
                            Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide
                            Cohort Study From Sweden. JAMA Intern Med 2017; 177(11):1605-12.</p>
                        <p class="mb-2">4. Aaltonen KJ, Joensuu JT, Virkki L, <i>et al</i>. Rates of serious infections and
                            malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor
                            inhibitor or rituximab therapy. J Rheumatol 2015; 42(3):372-8.</p>
                        <p class="mb-2">5. Silva-Fernández L, Lunt M, Kearsley-Fleet L, <i>et al</i>. British Society for
                            Rheumatology Biologics Register (BSRBR) Control Centre Consortium. The incidence of cancer in
                            patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or
                            rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid
                            Arthritis. Rheumatology (Oxford) 2016; 55(11):2033-9. </p>
                        <p class="mb-2">6. Xie W, Xiao S, Huang Y, <i>et al</i>. A meta-analysis of biologic therapies on risk of
                            new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy.
                            Rheumatology 2020; 59:930-9.</p>
                        <p class="mb-2">7. Ytterberg SR, Bhatt DL, Mikuls TR, <i>et al</i>. Cardiovascular and Cancer Risk with
                            Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022; 386:316-26.</p>
                        <p class="mb-2">8. Manfredsdottir VF, Vikingsdottir T, Jonsson T, <i>et al</i>. The effects of tobacco
                            smoking and rheumatoid factor seropositivity on disease activity and joint damage in early
                            rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(6):734-40. </p>

                    </div>
                    <div id="references" class="box-item diff-1 references mt-0">
                        <h3 class="common-title text-deeppink mb-3">
                            References (RA, fibromyalgia and osteoporosis):
                        </h3>
                        <p class="mb-2">1. Sinigaglia L, Nervetti A, Mela Q, <i>et al</i>. A multicenter cross sectional study on
                            bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid
                            Arthritis. J Rheumatol 2000; 27(11):2582-9.</p>
                        <p class="mb-2">2. van Staa TP, Geusens P, Bijlsma JW, <i>et al</i>. Clinical assessment of the long-term
                            risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(10):3104-12.
                        </p>
                        <p class="mb-2">3. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, <i>et al</i>. Changes in bone
                            mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008;
                            67(6):823-8.</p>
                        <p class="mb-2">4. Adami G, Saag KG. Osteoporosis Pathophysiology, Epidemiology, and Screening in
                            Rheumatoid Arthritis. Curr Rheumatol Rep 2019; 21(7):34. </p>
                        <p class="mb-2">5. Siu S, Haraoui B, Bissonnette R, <i>et al</i>. A meta-analysis of tumor necrosis factor
                            inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing
                            spondylitis trials. Arthritis Care Res (Hoboken) 2015; 67(6):754-64.</p>
                        <p class="mb-2">6. Haliloglu S, Carlioglu A, Akdeniz D, <i>et al</i>. Fibromyalgia in patients with other
                            rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int 2014;
                            34:1275-80.</p>
                        <p class="mb-2">7. Duffield SJ, Miller N, Zhao S, <i>et al</i>. Concomitant fibromyalgia complicating
                            chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford)
                            2018; 57(8):1453-60. </p>
                        <p class="mb-2">8. Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid
                            fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol 2019; 33(3):101423. </p>
                        <p class="mb-2">9. Davies P, Kennedy J, Nair J, <i>et al</i>. O34 Cost-effectiveness of a clinical nurse
                            specialist performing targeted musculoskeletal ultrasound in the rheumatology clinic.
                            Rheumatology 2018; 57(suppl 3):key075.216.</p>
                        <p class="mb-2">10. Salaffi F, Di Carlo M, Farah S, <i>et al</i>. Prevalence of frailty and its associated
                            factors in patients with rheumatoid arthritis: a cross-sectional analysis. Clin Rheumatol 2019;
                            38(7):1823-30.</p>
                        <p class="mb-2">11. Durán J, Combe B, Niu J, <i>et al</i>. The effect on treatment response of fibromyalgic
                            symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort. Rheumatology
                            2015; 54:2166-70. </p>
                        <p class="mb-2">12. van Staa TP, Geusens P, Bijlsma JW, <i>et al</i>. Clinical assessment of the long-term
                            risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(10):3104-12.
                        </p>
                        <p class="mb-2">13. Arthritis Society. What are the risk factors for FM? Available at:
                            https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/fibromyalgia. Accessed March
                            2022.</p>
                        <p class="mb-2">14. Lee YC, Lu B, Boire G, <i>et al</i>. Incidence and predictors of secondary fibromyalgia
                            in an early arthritis cohort. Ann Rheum Dis 2013; 72(6):949-54.</p>
                        <p class="mb-2">15. García-Leiva JM, Carrasco JL, Slim M, <i>et al</i>. Celiac symptoms in patients with
                            fibromyalgia: a cross-sectional study. Rheumatol Int 2015; 35(3):561-7. </p>
                    </div>

                </div>
                <div class="right-sidebar">

                </div>
            </div>
        </section>
        <footer>
            <div class="container">
                <p class="text-white">
                    Copyright 2022. This learning program is supported by Pfizer Canada. The faculty had full editorial
                    control over the contents of the program. The contents of the program are aligned with the approved
                    Canadian product monographs. Opinions expressed are those of the presenters and not necessarily Pfizer
                    Canada. This program is intended for healthcare professionals only.
                </p>
            </div>
        </footer>



        <script src="assets/js/jquery.min.js"></script>
        <script src="assets/js/bootstrap.bundle.min.js"></script>
        <script src="assets/js/index.js"></script>
    </body>

</html>